Evidence map›Paper›PMID 31712223›Full record

ReviewCold Spring Harbor perspectives in medicine2020

The Elimination of Hepatitis C as a Public Health Threat.

Margaret Hellard, Sophia E Schroeder, Alisa Pedrana, Joseph Doyle, Campbell Aitken

Abstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Contemporary global epidemiology of cirrhosis.Hepatology communications · 2026
    Review
  3. Article
  4. Article
  5. A Bibliometric Analysis of the HCV Drug-Resistant Majority and Minority Variants.International journal of environmental research and public health · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Margaret HellardDisease Elimination Program, Burnet Institute, Melbourne 3004, Australia.
Sophia E SchroederDisease Elimination Program, Burnet Institute, Melbourne 3004, Australia.
Alisa PedranaDisease Elimination Program, Burnet Institute, Melbourne 3004, Australia.
Joseph DoyleDisease Elimination Program, Burnet Institute, Melbourne 3004, Australia.
Campbell AitkenDisease Elimination Program, Burnet Institute, Melbourne 3004, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus is a global public health threat, affecting 71 million people worldwide. Increasing recognition of the impact of this epidemic and recent advances in biomedical and technical approaches to hepatitis C prevention and cure have provided impetus for the World Health Organization (WHO) to call for global elimination of hepatitis C as a public health threat by 2030. This work reviews the feasibility of hepatitis C elimination and pathways to overcome existing and potential future barriers to elimination. Drawing on cost-effectiveness modeling and providing examples of successful implementation efforts across the globe, we highlight the resources and strategies needed to achieve hepatitis C elimination. A timely, multipronged response is required if the 2030 WHO elimination targets are to be achieved. Importantly, achieving hepatitis C elimination will also benefit the community well beyond 2030.

Indexed as

Health Services AccessibilityPublic HealthAntiviral AgentsForecastingGlobal Burden of DiseaseHepatitis CHumansWorld Health OrganizationAntiviral Agents

Identifiers

PMID31712223
PMCPMC7117951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.